|drug601||CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) Wiki||1.00|
|drug1140||EU-approved RoActemra Wiki||1.00|
|D001172||Arthritis, Rheumatoid NIH||0.30|
There is one clinical trial.
Randomized, double-blind, placebo-controlled pilot study to evalaute viral load in saliva of COVID19+ patients using quantitative PCR, before and after use of active or placebo rinses
Description: change versus baseline in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCRMeasure: exploratory change in viral load Time: baseline (pre-rinse) and 15 min, 1 hour, 2 hours and 5 days after initial oral rinse
Description: number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCRMeasure: number of patients who have decrease in viral load of SARS-CoV-2 in spontaneous saliva measured by quantitative PCR Time: 15 min, 1 hour, 2 hours and 5 days after initial oral rinse
Description: description of adverse eventsMeasure: number of patients with adverse events during 5 days study duration Time: through study completion in day 5
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports